NCT06642584

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IV

A Study Investigating the Pharmacokinetic Properties When Dosing Different Formulations of Semaglutide to Healthy Male Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 90 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: Male
• Age: 18 Years – 64 Years
• Healthy volunteers: Accepted

Summary

This study is conducted to compare four different tablets containing the investigational medicine semaglutide at the same dose. It is done to test how semaglutide in each of the tablet versions is taken up in the body. Which treatments participants will receive is decided by chance. The study will last for about 28 weeks. The study will enroll healthy male participants.

Conditions

• Healthy Volunteers Type 2 Diabetes

Interventions

Type	Name	Description
DRUG	Semaglutide B	Semaglutide B will be administered subcutaneously.
DRUG	Semaglutide J	Semaglutide J will be administered as oral tablets.
DRUG	Semaglutide L	Semaglutide L will be administered as oral tablets.
DRUG	Semaglutide M	Semaglutide M will be administered as oral tablets.
DRUG	Semaglutide N	Semaglutide N will be administered as oral tablets.

Timeline

• Start date: 2024-10-15
• Primary completion: 2025-07-10
• Completion: 2025-08-13
• First posted: 2024-10-15
• Last updated: 2025-10-20

Locations

1 site across 1 country: Canada